# Hongbin Zhou

> Hongbin Zhou is a Series A investor at Legend Capital backing Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Legend Capital](https://shizune.co/investors/profile/legend-capital)
- Total investments: 4
- Last investment: Apr 2023
- Lead investor: 100%
- Last updated: Aug 2026

Hongbin Zhou is a Series A investor at Legend Capital focused on Health Care and Biotechnology. Hongbin Zhou is based out of Beijing and is the director of Atour Hotel. Hongbin previously worked at Milkway Chemical Engineering Supply Chain Service as a director. Hongbin Zhou attended the Fudan University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |
| Biopharma | 1 | 25% |
| Consulting | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 25% |
| Series B | 1 | 25% |
| Series C | 1 | 25% |
| Series E | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 3 | 75% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tripod Preclinical Research Laboratories | Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), foodadditives, biologics，pesticides，veterinary drugs, and new cosmetics. | $5.5M | Series C | Apr 12, 2023 |  |
| APTBIO | APTBIO was initiated by Shanghai Institutes for Biological Sciences under Chinese Academy of Sciences in 2004, and is mainly engaged in the application of mass spectrometry technology. The so-called mass spectrometry technology is to measure the quality of protein molecules to carry out the identification of protein molecules, the modification ofprotein molecules and the study of protein molecule interactions. |  | Series B | Aug 16, 2022 |  |
| ClinChoice | Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trialdesigns, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China. | $150M | Series E | Jul 04, 2022 |  |
| Nest | Nest Bio is a manufacturer of disposable medical consumables, focusing on the R&D and production of cell culture consumables. |  | Series A | Jun 07, 2022 |  |

4 of 4 investments shown.

## Co-investors
- [China Pacific Insurance](https://shizune.co/investors/profile/china-pacific-insurance) — VC Fund, 2 deals together
- [Apricot Capital](https://shizune.co/investors/profile/apricot-capital) — VC Fund, 1 deal together
- [Cornerstone Capital Bank](https://shizune.co/investors/profile/cornerstonecapital) — VC Fund, 1 deal together
- [Co-Stone Venture Capital](https://shizune.co/investors/profile/co-stone-capital) — VC Fund, 1 deal together
- [Defu Capital](https://shizune.co/investors/profile/defu-capital) — VC Fund, 1 deal together
- [GL Capital](https://shizune.co/investors/profile/gl-capital) — VC Fund, 1 deal together

## About Legend Capital

VC Fund · Beijing, China

Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.

5 contacts available at Legend Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Hongbin Zhou | Managing Director | https://shizune.co/investors/profile/zhou-hongbin |
| Jianqing Wang | Managing Director and Chief Management Advisor | https://shizune.co/investors/profile/wang-jianqing |
| Joon Park | Co-CIO | https://shizune.co/investors/profile/joon-sung-park |
| Tony WANG | VP | https://shizune.co/investors/profile/tony-wang-6 |
| Yi Kang | Director | https://shizune.co/investors/profile/yi-kang |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Hongbin Zhou invest in?

Hongbin Zhou invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hongbin Zhou last invest?

The most recent investment recorded for Hongbin Zhou closed in Apr 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co